Quantification of Phosphorylated Alpha-synuclein in Cutaneous Biopsies as a Prospective Biomarker in Parkinson's Disease

N/AActive Not RecruitingNCT06621602

CND Life Sciences100 enrolled

Overview

This study aims to assess the levels of phosphorylated alpha-synuclein (P-SYN) in patients with Parkinson's disease and REM Behavior Disorder using a minimally invasive skin punch biopsy. It seeks to understand the natural progression of P-SYN deposition over time to explore the potential of P-SYN quantification as a biomarker for disease progression.

This is a prospective, longitudinal study involving 75 Parkinson's disease patients and 25 patients with REM Behavior Disorder. Each participant will undergo a baseline evaluation followed by follow-ups every six months over an 18-month period. The evaluations will include clinical assessments, neurologic exams, and skin biopsies from three locations. Data will be collected on disease progression and the amount of P-SYN in cutaneous nerve fibers.

Study Type

OBSERVATIONAL

Enrollment

100

Conditions

REM Behavior Disorder Parkinson Disease

Eligibility

Sex: ALLMin age: 50 YearsMax age: 85 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Male and female 50 to 85 years of age 2. Clinical confirmed diagnosis of Parkinson's disease or REM Sleep Behavior Exclusion Criteria: 1. Clinical evidence of severe vascular disease (history of ulceration, poor wound healing or vascular claudication) 2. History of allergic reaction to Lidocaine for local anesthesia needed for skin biopsies 3. Use of blood thinners (Plavix or Aspirin used separately is allowed) 4. Significantly impaired wound healing or history of scarring or keloid formation

Locations (18)

CND Life Sciences

Scottsdale, Arizona, United States

Movement Disorders Center of Arizona

Scottsdale, Arizona, United States

Outcomes

Primary Outcomes

Changes in phosphorylated alpha-synuclein and clinical assessments from Baseline at 18 months

The accuracy of the pathological test in detecting α-synuclein aggregation and deposition in skin punch biopsies. Measurement of the quantity of phosphorylated alpha-synuclein (P-SYN) in each biopsy to determine whether cutaneous biopsies can serve as a biomarker for changes in P-SYN deposition over time .

Time frame: 18 months

Changes in phosphorylated alpha-synuclein and clinical assessments from Baseline at 18 months

The precision of the pathological test in detecting α-synuclein aggregation and deposition in skin punch biopsies. Measurement of the quantity of phosphorylated alpha-synuclein (P-SYN) in each biopsy to determine whether cutaneous biopsies can serve as a biomarker for changes in P-SYN deposition over time . Time Frame: 18 months

Time frame: 18 months

Changes in phosphorylated alpha-synuclein and clinical assessments from Baseline at 18 months

The sensitivity of the pathological test in detecting α-synuclein aggregation and deposition in skin punch biopsies. Measurement of the quantity of phosphorylated alpha-synuclein (P-SYN) in each biopsy to determine whether cutaneous biopsies can serve as a biomarker for changes in P-SYN deposition over time . Time Frame: 18 months Time Frame: 18 months

Time frame: 18 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.